Oral administration of cannabidiol is already proven effective for many applications. An area of major concern, however, is bioavailability. We have developed the CBDispersion System™ precisely to address this issue, with resulting benefits both to product users and to manufacturers employing CQLabs proprietary technology.
Cannabinoids, including CBD, are known to have low oral bioavailability of approximately 5-10%, requiring administration of 10 to 20 times more material than actually reaches the systemic bloodstream. As pure cannabinoids are highly expensive material, the resulting increase in expense is enormous. Improving bioavailability by a factor of 3-4x as is achieved with the CBDispersion System™ cuts CBD materials cost by 67% - 75%.
Low oral bioavailability of active ingredients such as CBD provides disadvantage for a further reason as well. Oral bioavailability typically varies between individuals, with greater potential variation at lower bioavailability percentages. By improving bioavailability, the CBDispersion System™ reduces causes of both day-to-day and inter-individual variability.
The CBDispersion System™ improves bioavailability by utilizing a self-nanoemulsifying system targeted to increase lymphatic delivery and by inhibiting enzymatic deactivation of CBD. Further, it does this in a way enabling convenient encapsulation or tableting.
The CQLabs CBDispersion System™
The CQLabs CBDispersion System™ benefits the user with improved bioavailability and consistency, and the manufacturer with drastically reduced materials costs.
Proprietary IP
CQLabs has developed patent-pending nanoemulsion systems which not only water-solubilize CBD and other cannabinoids (more precisely, they disperse cannabinoids into clear, nano-scale transparent solution) but optimize their uptake, particularly lymphatic uptake. Further, the CQLabs formulations inhibit enzymatic deactivation.
The proprietary compositions provide convenient powder fill of capsules and may be tabletted or incorporated into softgels or even beverages.
Formulations provide fast delivery, apparent to the user within 15 minutes of administration, as well as 4x bioavailability improvement at the 12 hour time point. Time-release formulations are being developed as well.
In a study, pure (99+%) CBD was administered at doses varying from 25 to 80 mg. Blood levels were measured at 4 hours to correspond with the expected peak with powder administration, and 12 hours as a representative measurement of the longer-term effect. CBD was separately administered as CQLabs CBDispersion™ at doses of 20 mg CBD. Blood levels were measured at 1.5 hours, estimated with this delivery system to be the expected peak, and at 12 hours as a representative measurement of longer-term effect.
Per milligram administered, the CBDelivery system outperformed CBD powder by 3.2 times at peak, and 4.3 times at 12 hours.
An upcoming clinical will provide full time course and AUC measurements.
DOWNLOAD DATA
CQLabs is first producing improved delivery of CBD for both human and veterinary applications. Ongoing research for following products includes other cannabinoids inclusive of cannabichromene, cannabidiolic acid, cannabidivarin, cannabigerol, cannabigerolic acid, cannabinodiol, cannabinol, cannabinolic acid, tetrahydrocannabinolic acid isomers, tetrahydrocannabinol isomers, tetrahydrocannabivarin isomers, and prodrugs thereof.
Area of Focus
